The Center for Applied Health Sciences
Canfield, Ohio, 44406, United States
NCT Number: NCT05573607
This study is a double-blind, randomized, two-arm, placebo-controlled trial of apparently healthy men and women to be recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences). Subjects will attend four study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work [also HgA1c, insulin], background baseline diet). Over the next 12 weeks, subjects will attend Visits 2-4, wherein assessments of serum glucose, insulin, HOMA-IR, 2-hour glucose tolerance test (GTT), HgA1c, C-reactive protein, adiponectin, ferritin, waist circumference, quality of life questionnaire, and various visual analog scales for appetite, satiety, and cravings will be made.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Not applicable
Canfield, Ohio, 44406, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Provide voluntary signed and dated informed consent. Be in good health as determined by medical history and routine blood chemistries.
Age between the ages of 21 and 65 (inclusive). Body Mass Index of 18.5-34.99 (inclusive). Body weight of at least 120 pounds. Fasting blood sugar of 100-125 (inclusive) OR HgA1c of 5.7-6.4% (inclusive). Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic bloodpressure < 90 mm Hg.
Normal seated, resting heart rate (<90 per minute). Willing to duplicate their previous 24-hour diet, refrain from caffeine for 12 hrs and exercise for 24 hr prior to each trial, and fast for 10 hours prior each of the treatments.
Exclusion criteria
History of unstable or new-onset cardiovascular or cardiorespiratory disease. History of diabetes, or other endocrine disorder. Fasting blood sugar of > 125 mg/dL or HgA1c of > 6.4%. History of use of medications or dietary supplements known to affect glycemia or insulinemia.
History of hyperparathyroidism or an untreated thyroid disease. History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
Prior gastrointestinal bypass surgery (Lapband), etc. Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.).
Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of- Analysis.
Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
Maltodextrin tablet
A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
Time frame: change from baseline to week 12
measurement of glucose in blood
Time frame: change from baseline to week 12
measurement of insulin in blood
Time frame: change from baseline to week 12
cravings as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings.
Time frame: change from baseline to week 12
satiety as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings.
Time frame: change from baseline to week 12
measurement of adiponectin in blood
Time frame: change from baseline to week 12
measurement of blood urea nitrogen in blood
Time frame: change from baseline to week 12
measurement of creatinine in blood
Time frame: change from baseline to week 12
measurement of alanine aminotransferase in blood
Time frame: change from baseline to week 12
measurement of aspartate aminotransferase in blood
Time frame: change from baseline to week 12
health status as measured with the SF-36 questionnaire, where scores range from 0 to 100, and higher values represent better health status.
The Center for Applied Health Sciences, LLC
Industry
Effects of a Dietary Supplement Containing Salacia Extract, Citrus Bioflavonoids, and Trivalent Chromium on Markers of Glucose Control and Quality of Life: A Randomized, Placebo-Controlled, Double-Blind Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07043478
Blood Glucose, Healthy
London, Ontario, Canada
View Trial DetailsNCT07187648
Blood Glucose, Blood-Borne Infections
Makassar, South Sulawesi, Indonesia
View Trial DetailsNCT06497972
Blood Glucose
Winnipeg, Manitoba, Canada
View Trial DetailsNCT06458946
Blood Glucose, Blood Insulin
Addison, Illinois, United States
View Trial Details